n (%) | irRC | RECIST | ||
---|---|---|---|---|
Immunotherapy-Naive (n = 39) | Prior Immunotherapy (n = 11) | Immunotherapy-Naive (n = 39) | Prior Immunotherapy (n = 11) | |
Objective response rate | 10 (25.6) | 0 | 9 (23.1) | 0 |
Complete response | 3 (7.7) | 0 | 3 (7.7) | 0 |
Partial response | 7 (17.9) | 0 | 6 (15.4) | 0 |
Stable disease | 15 (38.5) | 4 (36.4) | 10 (25.6) | 3 (27.3) |
Disease control rate | 25 (64.1) | 4 (36.4) | 19 (48.7) | 3 (27.3) |
Progressive disease | 7 (17.9) | 5 (45.5) | 15 (38.5) | 6 (54.5) |
Missing | 7 (17.9) | 2 (18.2) | 5 (12.8) | 2 (18.2) |
irRC immune-related response criteria, RECIST Response Evaluation Criteria in Solid Tumors